Larvol Delta - Clinical-Validation-and-Mechanistic-Understanding-of-Novel-DNA-pol-IIIC-Inhibitors-to-treat-Grampositive-Bacterial-Infections-Ibezapolstat-advancing-into-global-Phase-3-Clinical-Trials-for-C-difficile-Infection

ibezapolstat (ACX-362E) - Acurx Pharma

https://idweek2025.eventscribe.net/fsPopup.asp?PresentationID=1680305&mode=presInfo

Robert J. DeLuccia

Sep 3, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next